Pharma’s Growing Headache: Where Can Investors Find Relief?

June 5, 2025
You must provide your professional email address to view this content.

The U.S. is the pharmaceutical industry’s biggest customer—and it’s now also its biggest source of disruption. While regulatory risk is a constant in the sector, the combination of tariffs, pricing mandates, and spending cuts signals a systematic shift. As pricing reform and trade actions reshape the pharmaceutical landscape, investors must stay alert to policy volatility and adjust their exposure accordingly. With multiple levers in motion and few clear timelines, this is a difficult environment for investors to navigate. We see heightened risk for companies tied to manufacturing in India, China, and Europe (especially Ireland), and for those heavily reliant on Medicaid revenue. Opportunities for resilience lie with firms producing in the U.S., those less exposed to targeted regions or public reimbursement—though even here, implementation risk remains high and unpredictable.

Disclaimer / Securities Disclosure

The author(s) of this research note do (does) not personally hold a any position in any of the above-mentioned securities.
Nordis Capital (SMS’ sister company) does hold GSK, Novo Nordisk, Vertex, Regeneron, United Therapeutics and Eli Lilly in its funds.

DISCLAIMER
© Sustainable Market Strategies, a division of SMS Financial Technologies inc. Redistribution prohibited without prior consent. This report has been prepared by Sustainable Market Strategies mainly for distribution to market professionals and institutional investors. It should not be considered as investment advice or a recommendation to purchase any particular security, strategy, or investment product. References to specific securities and issuers are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed.